Global Adrenocorticotropic Hormone (ACTH) Market – Industry Trends and Forecast to 2029

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Global Adrenocorticotropic Hormone (ACTH) Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Apr 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Adrenocorticotropic Hormone Acth Market

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period
2022 –2029
Diagram Market Size (Base Year)
USD 1.38 Billion
Diagram Market Size (Forecast Year)
USD 2.20 Billion
Diagram CAGR
%
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Global Adrenocorticotropic Hormone (ACTH) Market, By Source (Natural, Synthetic), Application (Rheumatology, Neurology, Nephrotic Syndrome, Ophthalmology, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029.

Adrenocorticotropic Hormone (ACTH) Market

 Market Analysis and Size

In recent years, the adrenocorticotropic hormone (ACTH)? market is anticipated to grow rapidly during the forecast period. The COVID-19 pandemic is being managed by the whole US healthcare system, which is planning, preparing, and collaborating. Manufacturers in the adrenocorticotropic hormone (ACTH) industry are attempting to understand the care habits of high-risk patients and those with respiratory disorders in order to sustain continuous supply chains. Manufacturers are developing solid supply chains with urgent care centres, retail clinics in pharmacies, and workplace clinics to keep economies operating during the epidemic. Because emergency rooms are already overburdened, these places can operate as wetlands, absorbing some of the overflow of sick and healthy patients.

Data Bridge Market Research analyses that the adrenocorticotropic hormone (ACTH)? market was valued at USD 1.38 billion in 2021 and is expected to reach USD 2.20 billion by 2029, registering a CAGR of 6.00% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

The pituitary gland, a tiny gland near the base of the brain, produces adrenocorticotropic hormone (ACTH)?. Adrenocorticotropic hormone (ACTH)? regulates the production of cortisol, another hormone. The adrenal glands, which are two tiny glands positioned above the kidneys, produce cortisol.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Source (Natural, Synthetic), Application (Rheumatology, Neurology, Nephrotic Syndrome, Ophthalmology, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Hikma Pharmaceuticals PLC (UK), Merck & Co., Inc. (US), Mallinckrodt (US), Avantor, Inc. (US), Merck KGaA (Germany),  Ferring B.V. (Switzerland), Viatris, Inc. (US)

Market Opportunities

  • Increase in the number of emerging markets
  • Increase in the number of research and development activities
  • Rising approvals and launches

Adrenocorticotropic Hormone (ACTH)? Market Dynamics

Drivers

  • Rise in the use of adrenocorticotropic hormone (ACTH) products

Over the last few years, the use of adrenocorticotropic hormone (ACTH) has expanded dramatically. The adrenocorticotropic hormone is currently used to treat nephrotic syndrome, ophthalmology, rheumatology, Addison disease, Cushing syndrome, and Cushing illness, among other conditions. The increased use of adrenocorticotropic hormone (ACTH) products produces a tremendous demand for these goods and acts as a market driver.

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of adrenocorticotropic hormone (ACTH)? market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the adrenocorticotropic hormone (ACTH)? market. Additionally, high disposable income and surging prevalence of multiple sclerosis and infantile spasms will expand the adrenocorticotropic hormone (ACTH)? market. Along with this, rising incidences of stress and anxiety among people and favourable reimbursement policies will enhance the market's growth rate.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the adrenocorticotropic hormone (ACTH)? market growth. Rising approvals and launches with adrenocorticotropic hormone (ACTH) will further propel the market’s growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the adrenocorticotropic hormone (ACTH)? market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the drug development and distribution? will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the adrenocorticotropic hormone (ACTH)? market. Additionally, side effects of adrenocorticotropic hormone (ACTH)? and lack of awareness will act as market restraints and further impede the market's growth rate during the forecast period of 2022-2029.

This adrenocorticotropic hormone (ACTH)? market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the adrenocorticotropic hormone (ACTH)? market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Adrenocorticotropic hormone (ACTH)? market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Adrenocorticotropic Hormone (ACTH)? Market

Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This can be ascribed to severe disruptions in their respective manufacturing and supply-chain operations, resulting from multiple precautionary lockdowns and other limitations imposed by governments all over the world. The inkjet printers market is no exception. Furthermore, consumer preferences has decreased as people are now much more concentrated on removing non-essential expenses from their budgets as the wider economic situation of most people has been adversely impacted by this outbreak. Over the forecast period, the aforementioned factors are likely to have a negative impact on the adrenocorticotropic hormone (ACTH) market's revenue trajectory.

Global Adrenocorticotropic Hormone (ACTH)? Market Scope

The adrenocorticotropic hormone (ACTH)? market is segmented on the basis of source, application, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Source

  • Natural
  • Synthetic

On the basis of source, the global adrenocorticotropic hormone (ACTH)market is segmented into natural, and synthetic.

Application

  • Rheumatology
  • Neurology
  • Nephrotic Syndrome
  • Ophthalmology
  • Others

On the basis of application, the global adrenocorticotropic hormone (ACTH)market is segmented into rheumatology, neurology, nephrotic syndrome, ophthalmology and others.

End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

On the basis of end-users, the adrenocorticotropic hormone (ACTH)? market is segmented into hospitals, specialty clinics, homecare and others.

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

On the basis of distribution channel, the adrenocorticotropic hormone (ACTH)? market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.

Adrenocorticotropic Hormone (ACTH)? Market Regional Analysis/Insights

The adrenocorticotropic hormone (ACTH)? market is analysed and market size insights and trends are provided by country, source, application, end-users and distribution channel as referenced above.

The countries covered in the adrenocorticotropic hormone (ACTH)? market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the adrenocorticotropic hormone (ACTH) market because of the increase in the number of research and development activities in this region. Additionally, growing presence of major key players will further propel the market’s growth rate in this region.

Asia-Pacific is expected to grow during the forecast period of 2022 to 2029 due to rising healthcare expenditure and increasing government initiatives to improve healthcare infrastructure in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Adrenocorticotropic Hormone (ACTH)? Market Share Analysis

The Adrenocorticotropic hormone (ACTH)? market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to adrenocorticotropic hormone (ACTH)? market.

Some of the major players operating in the adrenocorticotropic hormone (ACTH)? market are:

  • Pfizer Inc. (US)
  • GlaxoSmithKline plc (UK)
  • Merck & Co., Inc. (US)
  • Novartis AG (Switzerland)
  • Hikma Pharmaceuticals PLC (UK)
  • Avantor, Inc. (US)
  • Ferring B.V. (Switzerland)
  • Viatris, Inc. (US)
  • Merck KGaA (Germany)


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Adrenocorticotropic Hormone (ACTH) Market will be projected to grow at a CAGR of 6.00% during forecast by 2029.
The Adrenocorticotropic Hormone (ACTH) Market will be projected at USD 2.20 billion during forecast by 2029.
On the basis of application, the Adrenocorticotropic Hormone (ACTH) Market is segmented into Rheumatology, Neurology, Nephrotic Syndrome, Ophthalmology, Others.
The major players operating in the Adrenocorticotropic Hormone (ACTH) Market are Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Hikma Pharmaceuticals PLC (UK), Merck & Co., Inc. (US), Mallinckrodt (US), Avantor, Inc. (US), Merck KGaA (Germany), Ferring B.V. (Switzerland), Viatris, Inc. (US).